Pneumonia
Conditions
Brief summary
This study aims to explore the application of Electrical Impedance Tomography (EIT) in evaluating the effectiveness of OLE (Oscillatory Lung Expansion) airway clearance therapy for ICU patients with pulmonary infections. The goal is to understand the treatment response differences in patients with various causes of atelectasis (lung collapse). The study will include adult patients diagnosed with pulmonary infections and admitted to the ICU. The primary endpoint of the study is the peak cough flow (CPF), which measures the patient's ability to clear secretions from the lungs through coughing.
Interventions
DEVICEOscillatory Lung Expansion (OLE) Therapy
The OLE treatment device is used with synchronized nebulization of 10 ml of 0.9% NaCl solution. The continuous positive airway pressure during the exhalation phase is set to 10-20 cmH₂O, with continuous high-frequency oscillation at a rate of 170-230 times per minute. Each treatment session lasts for 10 minutes. The oxygen therapy parameters are set by the clinician and remain unchanged throughout the experiment.
Sponsors
Chinese PLA General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clearly diagnosed with pulmonary infection in the ICU, confirmed by microbiological tests (sputum culture, blood culture, etc.) or imaging tests (chest CT, chest X-ray); 2. Age ≥ 18 years; 3. Respiratory support is oxygen therapy (nasal cannula or face mask oxygen therapy); 4. Sputum volume \> 30 ml/day; 5. The patient or their legal representative signs the informed consent form.
Exclusion criteria
1. Pregnant or breastfeeding women; 2. Presence of respiratory or circulatory failure (requiring mechanical ventilation or vasopressor support to maintain circulation); 3. Untreated tension pneumothorax; 4. Body Mass Index (BMI) exceeding 50 kg/m²; 5. Rib deformities or severe thoracic deformities; 6. Contraindications for the use of EIT (such as implanted automatic cardiac defibrillators, acute chest trauma, subcutaneous implanted pumps, etc.); 7. Early withdrawal from the study or incomplete clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough Peak Flow | Day 1 |
Secondary
| Measure | Time frame |
|---|---|
| Lung Ultrasound Score | Day 1 |
| Sputum Viscosity | Day 1 |
| Cough Dysfunction Score | Day 1 |
| Heart rate | Day 1 |
| diastolic pressure | Day 1 |
| systolic pressure | Day 1 |
| Tidal Impedance Variation Before Cough (TIV) | Day 1 |
| End-Expiratory Lung Impedance (EELI) | Day 1 |
| Center of Ventilation (COV) | Day 1 |
| Ventilation Heterogeneity Index (GI) | Day 1 |
Countries
China
Contacts
CONTACTkaifei wang, Doctor
Outcome results
None listed